Corporate Banner
Satellite Banner
Technology Networks Header
Friday, September 19, 2014
Technology Networks
 
Register | Sign in
Home Page
  News
Return

Avaxia Biologics Receives IND Clearance from FDA for AVX-470

Published: Tuesday, November 27, 2012
Last Updated: Tuesday, November 27, 2012
Bookmark and Share
Clearance granted to initiate clinical program to evaluate AVX-470 as therapy for ulcerative colitis.


For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here


Scientific News
Novel Drug Targeting Leukemia Cells Enters Clinical Trial
Phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for CLL patients.
Salmonella - Why Live Vaccines May Be Most Effective
University of Cambridge researchers investigated the effectiveness of vaccines against Salmonella.
Intestinal Bacteria Needed for Strong Flu Vaccine Responses in Mice
Study demonstrate a dependency on gut bacteria for strong immune responses to the seasonal flu and inactivated polio vaccines.
Novel Immunotherapy Breast Cancer Vaccine
Vaccine Decreases Recurrence in HER2 Positive Breast Cancer Patients.
Cell ‘Memory’ Could be Key to Strengthen Vaccine Efficacy
Virginia Tech Carilion Research Institute scientists uncover immune system secret.
NIH-Led Scientists Discover HIV Antibody that Binds to Novel Target on Virus
The antibody, 35O22, prevents 62 percent of known HIV strains from infecting cells in the laboratory.
Breakthrough Melanoma Treatment, Keytruda, Developed
New immunotherapy launched in the US for treatment of adults with advanced melanoma, developed using antibody humanization expertise at UK’s MRC Technology.
Understanding and Improving the Body's Fight Against Pathogens
A*STAR scientists find new targets for modulating antibody response.
NIH to Launch Human Safety Study of Ebola Vaccine Candidate
Trial is First in Series of Accelerated Safety Studies of Ebola Vaccines.
MU Researchers Discover Protein's Ability To Inhibit HIV Release
TIM-family proteins have the ability to block the release of HIV and other viruses.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv